

Jason M White

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/837451/jason-m-white-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

205
papers

6,543
citations

45
h-index

71
g-index

209
ext. papers

7,288
ext. citations

4.8
avg, IF

5.88
L-index

#	Paper	IF	Citations
205	Partitioning of phytocannabinoids between faeces and water - Implications for wastewater-based epidemiology. <i>Science of the Total Environment</i> , 2022 , 805, 150269	10.2	0
204	A Taste for New Psychoactive Substances: Wastewater Analysis Study of 10 Countries. <i>Environmental Science and Technology Letters</i> , 2022 , 9, 57-63	11	5
203	Methcathinone in wastewater: Drug of choice, or artefact?. <i>Science of the Total Environment</i> , 2022 , 155696.2	10.2	0
202	International snapshot of new psychoactive substance use: Case study of eight countries over the 2019/2020 new year period. <i>Water Research</i> , 2021 , 193, 116891	12.5	12
201	A method and its application to determine the amount of cannabinoids in sewage sludge and biosolids. <i>Environmental Science and Pollution Research</i> , 2021 , 28, 59652-59664	5.1	2
200	Access to Controlled Medicines in Low-Income Countries: Listening to Stakeholders in the Field. <i>International Journal of Health Services</i> , 2021 , 51, 404-411	2	0
199	Application of catecholamine metabolites as endogenous population biomarkers for wastewater-based epidemiology. <i>Science of the Total Environment</i> , 2021 , 763, 142992	10.2	3
198	How the recreational stimulant market has changed: Case study in Adelaide, Australia 2016-2019. <i>Science of the Total Environment</i> , 2021 , 757, 143728	10.2	5
197	Changes in alcohol consumption associated with social distancing and self-isolation policies triggered by COVID-19 in South Australia: a wastewater analysis study. <i>Addiction</i> , 2021 , 116, 1600-1605	4.6	28
196	Impact of COVID-19 Controls on the Use of Illicit Drugs and Alcohol in Australia. <i>Environmental Science and Technology Letters</i> , 2021 , 8, 799-804	11	4
195	Pholedrine is a marker of direct disposal of methamphetamine. <i>Science of the Total Environment</i> , 2021 , 782, 146839	10.2	2
194	Adults with a history of recreational cannabis use have altered speech production. <i>Drug and Alcohol Dependence</i> , 2021 , 227, 108963	4.9	0
193	Determining changes in new psychoactive substance use in Australia by wastewater analysis. <i>Science of the Total Environment</i> , 2020 , 731, 139209	10.2	21
192	Anabasine-based measurement of cigarette consumption using wastewater analysis. <i>Drug Testing and Analysis</i> , 2020 , 12, 1393-1398	3.5	5
191	Determination of prescribed and designer benzodiazepines and metabolites in influent wastewater. <i>Analytical Methods</i> , 2020 , 12, 3637-3644	3.2	8
190	The complexities associated with new psychoactive substances in influent wastewater: The case of 4-ethylmethcathinone. <i>Drug Testing and Analysis</i> , 2020 , 12, 1494-1500	3.5	4
189	Towards an efficient method for the extraction and analysis of cannabinoids in wastewater. <i>Talanta</i> , 2020 , 217, 121034	6.2	14

188	Determination of 21 synthetic cathinones, phenethylamines, amphetamines and opioids in influent wastewater using liquid chromatography coupled to tandem mass spectrometry. <i>Talanta</i> , 2020 , 208, 120479	6.2	25
187	Amphetamine dependence in Australia. <i>Lancet, The</i> , 2020 , 396, 957	4.0	0
186	What is the drug of choice of young festivalgoers?. <i>Drug and Alcohol Dependence</i> , 2020 , 216, 108315	4.9	2
185	A sensitive analytical method for the measurement of neurotransmitter metabolites as potential population biomarkers in wastewater. <i>Journal of Chromatography A</i> , 2020 , 1612, 460623	4.5	9
184	Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. <i>Pain Medicine</i> , 2020 , 21, 2007-2008	2.8	1
183	Simultaneous determination of 24 opioids, stimulants and new psychoactive substances in wastewater. <i>MethodsX</i> , 2019 , 6, 953-960	1.9	22
182	Use of illicit amphetamines is associated with long-lasting changes in hand circuitry and control. <i>Clinical Neurophysiology</i> , 2019 , 130, 655-665	4.3	3
181	Salivary levels of alpha-amylase are associated with neurobehavioral alertness during extended wakefulness, but not simulated night-shift work. <i>Physiology and Behavior</i> , 2019 , 204, 1-9	3.5	3
180	Effects of strategic early-morning caffeine gum administration on association between salivary alpha-amylase and neurobehavioural performance during 50 h of sleep deprivation. <i>Accident Analysis and Prevention</i> , 2019 , 126, 160-172	6.1	0
179	Investigating the appearance of new psychoactive substances in South Australia using wastewater and forensic data. <i>Drug Testing and Analysis</i> , 2019 , 11, 250-256	3.5	19
178	Temporal and spatial dynamics of spinal sensorimotor processing in an intersegmental cutaneous nociceptive reflex. <i>Journal of Neurophysiology</i> , 2019 , 122, 616-631	3.2	3
177	New psychoactive substances: challenges for drug surveillance, control, and public health responses. <i>Lancet, The</i> , 2019 , 394, 1668-1684	4.0	100
176	Prevalence of self-reported movement dysfunction among young adults with a history of ecstasy and methamphetamine use. <i>Drug and Alcohol Dependence</i> , 2019 , 205, 107595	4.9	1
175	Measuring opioid dependence in chronic pain patients: A comparison between addiction clinic and pain clinic patient populations. <i>Journal of Opioid Management</i> , 2019 , 15, 285-293	0.8	1
174	Differential cardiovascular responses to cutaneous afferent subtypes in a nociceptive intersegmental spinal reflex. <i>Scientific Reports</i> , 2019 , 9, 19049	4.9	
173	Central Plasticity of Cutaneous Afferents Is Associated with Nociceptive Hyperreflexia after Spinal Cord Injury in Rats. <i>Neural Plasticity</i> , 2019 , 2019, 6147878	3.3	3
172	LC-HRMS suspect screening to show spatial patterns of New Psychoactive Substances use in Australia. <i>Science of the Total Environment</i> , 2019 , 650, 2181-2187	10.2	42
171	Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. <i>Pain Medicine</i> , 2019 , 20, 119-128	2.8	20

170	Investigating the correlation between wastewater analysis and roadside drug testing in South Australia. <i>Drug and Alcohol Dependence</i> , 2018 , 187, 123-126	4.9	9
169	Measuring spatial and temporal trends of nicotine and alcohol consumption in Australia using wastewater-based epidemiology. <i>Addiction</i> , 2018 , 113, 1127-1136	4.6	40
168	Upper limb function in children with attention-deficit/hyperactivity disorder (ADHD). <i>Journal of Neural Transmission</i> , 2018 , 125, 713-726	4.3	12
167	Medication induced sleepwalking: A systematic review. <i>Sleep Medicine Reviews</i> , 2018 , 37, 105-113	10.2	57
166	LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. <i>BMJ Open</i> , 2018 , 8, e020723	3	9
165	Qualitative and quantitative temporal analysis of licit and illicit drugs in wastewater in Australia using liquid chromatography coupled to mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2018 , 410, 529-542	4.4	35
164	Decreased salivary alpha-amylase levels are associated with performance deficits during sleep loss. <i>Psychoneuroendocrinology</i> , 2017 , 78, 131-141	5	14
163	Impaired psychomotor function and plasma methadone and levo-alpha-acetylmethadol (LAAM) concentrations in opioid-substitution patients. <i>Experimental and Clinical Psychopharmacology</i> , 2017 , 25, 223-233	3.2	
162	History of cannabis use is associated with altered gait. <i>Drug and Alcohol Dependence</i> , 2017 , 178, 215-222	4.9	9
161	Opioid antagonists with minimal sedation for opioid withdrawal. <i>The Cochrane Library</i> , 2017 , 5, CD002024	3.2	18
160	Buprenorphine for managing opioid withdrawal. <i>The Cochrane Library</i> , 2017 , 2, CD002025	5.2	49
159	Peripheral and central anatomical organization of cutaneous afferent subtypes in a rat nociceptive intersegmental spinal reflex. <i>Journal of Comparative Neurology</i> , 2017 , 525, 2216-2234	3.4	12
158	Wastewater analysis shows a large decrease in oxycodone use in Adelaide. <i>Medical Journal of Australia</i> , 2017 , 207, 88	4	1
157	Estimates of tobacco use by wastewater analysis of anabasine and anatabine. <i>Drug Testing and Analysis</i> , 2016 , 8, 702-7	3.5	26
156	Analysis of qualitative data from the investigation study in pregnancy of the ASSIST Version 3.0 (the Alcohol, Smoking and Substance Involvement Screening Test). <i>Midwifery</i> , 2016 , 34, 183-197	2.8	6
155	Movement Dysfunction as a Neuropathology of Illicit Stimulant Abuse 2016 , 219-228		
154	History of Illicit Stimulant Use Is Not Associated with Long-Lasting Changes in Learning of Fine Motor Skills in Humans. <i>Neural Plasticity</i> , 2016 , 2016, 9485079	3.3	4
153	Ethical considerations when researching with pregnant substance users and implications for practice. <i>Addictive Behaviors</i> , 2016 , 60, 242-3	4.2	2

152	Temporal trends in drug use in Adelaide, South Australia by wastewater analysis. <i>Science of the Total Environment</i> , 2016 , 565, 384-391	10.2	85
151	Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2016 , 25, 27-32	3.6	30
150	Alpha2-adrenergic agonists for the management of opioid withdrawal. <i>The Cochrane Library</i> , 2016 , CD002024	3.2	51
149	Acute opioid administration induces hypothalamic-pituitary-adrenal activation and is mediated by genetic variation in interleukin (IL)1B. <i>Pharmacology Biochemistry and Behavior</i> , 2015 , 138, 9-13	3.9	4
148	Trends in stimulant use in Australia: A comparison of wastewater analysis and population surveys. <i>Science of the Total Environment</i> , 2015 , 536, 331-337	10.2	29
147	Evaluation of DNA degradation using flow cytometry: promising tool for postmortem interval determination. <i>American Journal of Forensic Medicine and Pathology</i> , 2015 , 36, 104-10	1	18
146	Alpha2-adrenergic agonists for the management of opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2014 , CD002024		39
145	Towards finding a population biomarker for wastewater epidemiology studies. <i>Science of the Total Environment</i> , 2014 , 487, 621-8	10.2	97
144	Hand function is altered in individuals with a history of illicit stimulant use. <i>PLoS ONE</i> , 2014 , 9, e115771	3.7	7
143	Blocking endogenous opioids during development--do we understand the consequences?. <i>Addiction</i> , 2013 , 108, 251-2	4.6	3
142	Evaluation of pre-analysis loss of dependent drugs in wastewater: stability and binding assessments. <i>Drug Testing and Analysis</i> , 2013 , 5, 716-21	3.5	41
141	Increases in use of novel synthetic stimulant are not directly linked to decreased use of 3,4-methylenedioxy-N-methylamphetamine (MDMA). <i>Forensic Science International</i> , 2013 , 231, 278-83	2.6	46
140	Investigation of the Alcohol, Smoking, and Substance Involvement Screening Test (the ASSIST) Version 3.0 in Pregnancy. <i>Addictive Disorders and Their Treatment</i> , 2013 , 12, 123-135	0.5	9
139	Abnormal maximal finger tapping in abstinent cannabis users. <i>Human Psychopharmacology</i> , 2013 , 28, 612-4	2.3	7
138	Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. <i>PLoS ONE</i> , 2013 , 8, e56438	3.7	36
137	Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 786-94	3.8	19
136	Antidepressant-like effects of ecstasy in subjects with a predisposition to depression. <i>Addictive Behaviors</i> , 2012 , 37, 1189-92	4.2	12
135	Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 835-41	3.8	18

134	Dose-related effects of alcohol on cognitive functioning. <i>PLoS ONE</i> , 2012 , 7, e50977	3.7	70
133	ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. <i>Pharmacogenomics and Personalized Medicine</i> , 2012 , 5, 53-62	2.1	29
132	Comparison of pain models to detect opioid-induced hyperalgesia. <i>Journal of Pain Research</i> , 2012 , 5, 99-106	2.9	18
131	The effect of methadone on emotional reactivity. <i>Addiction</i> , 2012 , 107, 388-92	4.6	13
130	Patterns of symptom reporting during pregnancy comparing opioid maintained and control women. <i>Journal of Addiction Medicine</i> , 2012 , 6, 258-64	3.8	5
129	Motor cortex and corticospinal excitability in humans with a history of illicit stimulant use. <i>Journal of Applied Physiology</i> , 2012 , 113, 1486-94	3.7	16
128	Screening for use of alcohol, tobacco and cannabis in pregnancy using self-report tools. <i>Journal of Developmental Origins of Health and Disease</i> , 2012 , 3, 216-23	2.4	
127	Ineffective morphine treatment regimen for the control of Neonatal Abstinence Syndrome in buprenorphine- and methadone-exposed infants. <i>Journal of Developmental Origins of Health and Disease</i> , 2012 , 3, 262-70	2.4	10
126	Illicit stimulant use in humans is associated with a long-term increase in tremor. <i>PLoS ONE</i> , 2012 , 7, e52025	3.7	22
125	Antidepressant-like effects of 3,4-methylenedioxymethamphetamine in an animal model of depression. <i>Behavioural Pharmacology</i> , 2011 , 22, 758-65	2.4	9
124	OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 902-5	1.9	35
123	Marked decline in 3,4-methylenedioxymethamphetamine (MDMA) based on wastewater analysis. <i>Journal of Studies on Alcohol and Drugs</i> , 2011 , 72, 737-40	1.9	15
122	Pill content, dose and resulting plasma concentrations of 3,4-methylenedioxymethamphetamine (MDMA) in recreational EcstasyUsers. <i>Addiction</i> , 2011 , 106, 1293-300	4.6	45
121	Population drug use in Australia: a wastewater analysis. <i>Forensic Science International</i> , 2011 , 210, 69-73	2.6	118
120	Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects. <i>European Journal of Pain</i> , 2011 , 15, 293-8	3.7	14
119	(R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. <i>British Journal of Clinical Pharmacology</i> , 2010 , 70, 895-902	3.8	19
118	Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. <i>Addiction</i> , 2010 , 105, 146-54	4.6	83
117	Psychosocial treatment for methamphetamine use disorders: a preliminary randomized controlled trial of cognitive behavior therapy and Acceptance and Commitment Therapy. <i>Substance Abuse</i> , 2010 , 31, 98-107	3.8	77

116	The Psychostimulant Check-Up: A pilot study of a brief intervention to reduce illicit stimulant use. <i>Drug and Alcohol Review</i> , 2010 , 29, 169-76	3.2	3
115	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. <i>The Cochrane Library</i> , 2010 , CD002022	5.2	28
114	The effects of prenatal exposure to buprenorphine or methadone on infant visual evoked potentials. <i>Neurotoxicology and Teratology</i> , 2010 , 32, 280-8	3.9	36
113	Model of methadone-induced hyperalgesia in rats and effect of memantine. <i>European Journal of Pharmacology</i> , 2010 , 626, 229-33	5.3	14
112	Opioids: Heroin and Prescription Drugs 2010 , 1029-1048		0
111	Drug Addiction: From Basic Research to Therapy. <i>Drug and Alcohol Review</i> , 2009 , 28, 455-455	3.2	3
110	Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. <i>Drug and Alcohol Dependence</i> , 2009 , 103, 37-43	4.9	56
109	Buprenorphine for the management of opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2009 , CD002025		76
108	Alpha2-adrenergic agonists for the management of opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2009 , CD002024		31
107	Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. <i>Journal of Pain</i> , 2009 , 10, 316-22	5.2	122
106	Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 869-76	1.9	35
105	Opioid antagonists with minimal sedation for opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2009 , CD002021		25
104	Pharmacology of opioid agonists and antagonists 2009 , 15-53		
103	Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 83, 144-52	6.1	25
102	Pregnancy-related changes in tobacco, alcohol and cannabis use reported by antenatal patients at two public hospitals in South Australia. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2008 , 48, 248-54	1.7	29
101	Exposure to opioid maintenance treatment reduces long-term mortality. <i>Addiction</i> , 2008 , 103, 462-8	4.6	136
100	Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 640-7	3.8	16
99	Pharmacotherapy of methamphetamine addiction: an update. <i>Substance Abuse</i> , 2008 , 29, 31-49	3.8	89

98	Psychometric evaluation of the Amphetamine Cessation Symptom Assessment. <i>Journal of Substance Abuse Treatment</i> , 2008 , 34, 443-9	4.2	20
97	Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. <i>Journal of Substance Abuse Treatment</i> , 2008 , 35, 334-42	4.2	56
96	Inter- and intra-subject variability in ethanol pharmacokinetic parameters: effects of testing interval and dose. <i>Forensic Science International</i> , 2008 , 175, 65-72	2.6	9
95	Antinociceptive effects of high-dose remifentanyl in male methadone-maintained patients. <i>European Journal of Pain</i> , 2008 , 12, 926-33	3.7	13
94	Opioid maintenance: a comparative review of pharmacological strategies. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1-11	4	20
93	Opioids, Pain and Addiction: Cause and Consequence 2007 , 39-55		1
92	Buprenorphine for the management of opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD002025		50
91	Plasma drug concentrations and physiological measures in Rance partyRparticipants. <i>Neuropsychopharmacology</i> , 2006 , 31, 424-30	8.7	46
90	Effects of Pharmacotherapies for Opioid Dependence on ParticipantsRCriminal Behaviour and Expenditure on Illicit Drugs: An Australian National Evaluation (NEPOD). <i>Australian and New Zealand Journal of Criminology</i> , 2006 , 39, 171-189	1.9	11
89	A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). <i>Addictive Behaviors</i> , 2006 , 31, 371-87	4.2	19
88	Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. <i>Pain</i> , 2006 , 120, 267-275	8	65
87	Opioid antagonists with minimal sedation for opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD002021		8
86	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD002022		8
85	Maintenance Pharmacotherapy for Opioid Dependence and SF-36 Health Status: A Comparison With General Population Norms and Other Chronic Disorders. <i>Addictive Disorders and Their Treatment</i> , 2006 , 5, 155-164	0.5	10
84	Fluctuations in (R,S)-methadone pharmacokinetics and response among long-term methadone maintenance patients. <i>Addiction Biology</i> , 2006 , 11, 170-4	4.6	5
83	Switching between methadone and morphine for maintenance treatment of opioid dependence: impact on pain sensitivity and mood status. <i>American Journal on Addictions</i> , 2006 , 15, 311-5	3.7	14
82	Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. <i>British Journal of Clinical Pharmacology</i> , 2005 , 60, 404-13	3.8	19
81	The nature, time course and severity of methamphetamine withdrawal. <i>Addiction</i> , 2005 , 100, 1320-9	4.6	306

80	Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 742-55	3.8	63
79	Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. <i>British Journal of Clinical Pharmacology</i> , 2004 , 58, 536-41	3.8	15
78	Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. <i>British Journal of Clinical Pharmacology</i> , 2004 , 58, 609-17	3.8	35
77	Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. <i>Addiction</i> , 2004 , 99, 940-5	4.6	58
76	Use of radiotelemetry to evaluate respiratory depression produced by chronic methadone administration. <i>European Journal of Pharmacology</i> , 2004 , 484, 303-10	5.3	6
75	Baclofen prevents MDMA-induced rise in core body temperature in rats. <i>Drug and Alcohol Dependence</i> , 2004 , 74, 89-96	4.9	32
74	Evaluation of levo-alpha-acetylmethadol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis. <i>Drug and Alcohol Dependence</i> , 2004 , 76, 63-72	4.9	23
73	Pleasure into pain: the consequences of long-term opioid use. <i>Addictive Behaviors</i> , 2004 , 29, 1311-24	4.2	96
72	Changes in Methadone Concentration, Opioid Effects, and Opioid Withdrawal During Induction Onto Maintenance Treatment. <i>Addictive Disorders and Their Treatment</i> , 2004 , 3, 122-128	0.5	
71	Alpha2 adrenergic agonists for the management of opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2004 , CD002024		15
70	In-patient benzodiazepine withdrawal: comparison of fixed and symptom-triggered taper methods. <i>Drug and Alcohol Review</i> , 2003 , 22, 175-80	3.2	27
69	Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity. <i>Drug and Alcohol Review</i> , 2003 , 22, 425-31	3.2	8
68	Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. <i>Addiction</i> , 2003 , 98, 441-52	4.6	206
67	Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. <i>Drug and Alcohol Dependence</i> , 2003 , 69, 317-22	4.9	20
66	Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. <i>Drug and Alcohol Dependence</i> , 2003 , 71, 295-302	4.9	86
65	Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. <i>Drug and Alcohol Dependence</i> , 2003 , 72, 85-94	4.9	40
64	The contribution of the metabolite p-hydroxyamphetamine to the central actions of p-methoxyamphetamine. <i>Psychopharmacology</i> , 2002 , 160, 155-60	4.7	14
63	Alpha2-adrenergic agonists in opioid withdrawal. <i>Addiction</i> , 2002 , 97, 49-58	4.6	53

62	In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. <i>Addiction Biology</i> , 2002 , 7, 219-25	4.6	39
61	Comment on: Doverty et al., Hyperalgesic responses in methadone maintenance patients (<i>Pain</i> 2001;90:918). <i>Pain</i> , 2002 , 99, 609-610	8	1
60	Relationship between LAAM-methadone preference and treatment outcomes. <i>Drug and Alcohol Dependence</i> , 2002 , 66, 295-301	4.9	18
59	A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. <i>Drug and Alcohol Dependence</i> , 2002 , 68, 5-14	4.9	37
58	Which substitution pharmacotherapy is most effective in treating opioid dependence?. <i>Medical Journal of Australia</i> , 2002 , 176, 493-4	4	
57	Modification of d-amphetamine-induced responses by baclofen in rats. <i>Psychopharmacology</i> , 2001 , 153, 277-84	4.7	26
56	Precipitated withdrawal following codeine administration is dependent on CYP genotype. <i>European Journal of Pharmacology</i> , 2001 , 425, 159-64	5.3	7
55	Hyperalgesic responses in methadone maintenance patients. <i>Pain</i> , 2001 , 90, 91-6	8	215
54	Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. <i>Pain</i> , 2001 , 93, 155-163	8	120
53	Attenuation of morphine withdrawal signs by the GABA(B) receptor agonist baclofen. <i>Life Sciences</i> , 2001 , 70, 395-401	6.8	30
52	The acute effects of zolpidem compared to diazepam and lorazepam using radiotelemetry. <i>Neuropharmacology</i> , 2001 , 40, 717-21	5.5	27
51	The relationship between mood state and plasma methadone concentration in maintenance patients. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 78-84	1.7	54
50	The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability: part ii: the relationship between drug prevalence and drug concentration, and driver culpability. <i>Accident Analysis and Prevention</i> , 2000 , 32, 623-32	6.1	135
49	Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 427-40	3.8	89
48	Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 465-71	3.8	53
47	Changes in alcohol history taking and management of alcohol dependence by interns at The Royal Adelaide Hospital. <i>Medical Education</i> , 2000 , 34, 170-4	3.7	8
46	Comparison of methods for teaching clinical skills in assessing and managing drug-seeking patients. <i>Medical Education</i> , 2000 , 34, 285-91	3.7	18
45	The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability: part i: the prevalence of drug use in drive the drug-positive group. <i>Accident Analysis and Prevention</i> , 2000 , 32, 613-22	6.1	78

44	Systematic review processes and the management of opioid withdrawal. <i>Australian and New Zealand Journal of Public Health</i> , 2000 , 24, 427-31	2.3	5
43	Precipitated and spontaneous withdrawal following administration of lorazepam but not zolpidem. <i>Pharmacology Biochemistry and Behavior</i> , 2000 , 66, 361-9	3.9	21
42	Long-term abecarnil administration produces tolerance and withdrawal signs in the rat. <i>European Journal of Pharmacology</i> , 2000 , 394, 237-45	5.3	2
41	The management of opioid withdrawal. <i>Drug and Alcohol Review</i> , 2000 , 19, 309-318	3.2	14
40	Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2000 , 24, 955-77	5.5	43
39	Mechanisms of fatal opioid overdose. <i>Addiction</i> , 1999 , 94, 961-972	4.6	394
38	Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 65, 685-94	6.1	103
37	Regulation of opioid receptors by opioid antagonists: implications for rapid opioid detoxification. <i>Addiction Biology</i> , 1999 , 4, 391-7	4.6	3
36	Cardiovascular changes during morphine administration and spontaneous withdrawal in the rat. <i>European Journal of Pharmacology</i> , 1999 , 368, 25-33	5.3	17
35	Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. <i>Pharmacology Biochemistry and Behavior</i> , 1999 , 64, 29-34	3.9	46
34	Therapeutic use of cannabis: clarifying the debate. <i>Drug and Alcohol Review</i> , 1998 , 17, 445-52	3.2	3
33	Methadone-related overdose deaths in South Australia, 1984-1994: How safe is methadone prescribing?. <i>Medical Journal of Australia</i> , 1997 , 166, 302-305	4	37
32	Patterns of symptom complaints in methadone maintenance patients. <i>Addiction</i> , 1997 , 92, 1445-1455	4.6	76
31	The influence of restraint on blood pressure in the rat. <i>Journal of Pharmacological and Toxicological Methods</i> , 1997 , 38, 157-62	1.7	102
30	The effects of central and peripheral angiotensin on hypertension and nociception in rats. <i>Pharmacology Biochemistry and Behavior</i> , 1997 , 57, 37-41	3.9	17
29	Patterns of symptom complaints in methadone maintenance patients. <i>Addiction</i> , 1997 , 92, 1445-1456	4.6	5
28	Improvements in retention rates and changes in client group with methadone maintenance streaming. <i>Drug and Alcohol Review</i> , 1996 , 15, 83-8	3.2	16
27	Pharmacological properties of ketamine. <i>Drug and Alcohol Review</i> , 1996 , 15, 145-55	3.2	57

26	Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. <i>Addiction</i> , 1996 , 91, 39-45	4.6	50
25	Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. <i>Addiction</i> , 1996 , 91, 39-45	4.6	73
24	Characterization of GABAB ligands in vivo. <i>General Pharmacology</i> , 1995 , 26, 417-24		10
23	The renin angiotensin system and nociception in spontaneously hypertensive rats. <i>Life Sciences</i> , 1995 , 56, 1073-8	6.8	26
22	The effects of GABAB ligands on alcohol withdrawal in mice. <i>Pharmacology Biochemistry and Behavior</i> , 1994 , 49, 561-6	3.9	22
21	Twenty-four hour ambulatory monitoring of tremor, sweating, skin temperature and locomotor activity in the alcohol withdrawal syndrome. <i>Clinical Autonomic Research</i> , 1994 , 4, 15-8	4.3	7
20	Injecting behaviour and risky needle use amongst methadone maintenance clients. <i>Drug and Alcohol Dependence</i> , 1994 , 34, 113-9	4.9	13
19	Determinants of benzodiazepine prescribing and administration in a public hospital. <i>Pharmacopsychiatry</i> , 1993 , 26, 11-4	2	8
18	The role of GABAB receptors in mediating the stimulatory effects of ethanol in mice. <i>Psychopharmacology</i> , 1993 , 111, 219-24	4.7	42
17	Response to alcohol cues as a function of consumption level. <i>Drug and Alcohol Dependence</i> , 1991 , 27, 191-5	4.9	11
16	Cue reactivity in alcohol abusers: stimulus specificity and extinction of the responses. <i>Addictive Behaviors</i> , 1991 , 16, 211-21	4.2	84
15	Computerized Instruction of Word Discriminations with Retarded Children: An Examination of Two Whole-Word Fading Procedures. <i>Journal of Educational Technology Systems</i> , 1991 , 20, 31-43	8.2	3
14	A Computerized Procedure for Teaching Letter Formation Skills to Mentally Retarded Individuals. <i>Journal of Educational Technology Systems</i> , 1990 , 18, 185-190	8.2	3
13	Behavioral interactions between nicotine and diazepam. <i>Pharmacology Biochemistry and Behavior</i> , 1989 , 32, 479-82	3.9	10
12	Acquisition and extinction of an alcohol-opposite conditioned response in humans. <i>Psychopharmacology</i> , 1989 , 97, 355-7	4.7	13
11	Acute tolerance to alcohol: changes in subjective effects among social drinkers. <i>Psychopharmacology</i> , 1989 , 97, 365-9	4.7	38
10	Conditioned alcohol-like and alcohol-opposite responses in humans. <i>Psychopharmacology</i> , 1988 , 95, 87-94	4.7	55
9	Behavioral interactions between nicotine and caffeine. <i>Pharmacology Biochemistry and Behavior</i> , 1988 , 29, 63-6	3.9	21

8	The discriminative stimulus properties of mepyramine. <i>Life Sciences</i> , 1985 , 37, 1145-53	6.8	5
7	Schedule-induced wheel-running: effects of exposure to the schedule. <i>Physiology and Behavior</i> , 1985 , 34, 119-22	3.5	7
6	Effects of nicotine on schedule-controlled behaviour. Role of fixed-interval length and modification by mecamlamine and chlorpromazine. <i>Neuropharmacology</i> , 1985 , 24, 75-82	5.5	14
5	The effects of amphetamine and scopolamine on adjunctive drinking and wheel-running in rats. <i>Psychopharmacology</i> , 1984 , 82, 360-7	4.7	26
4	Three-choice drug discrimination: phencyclidine-like stimulus effects of opioids. <i>Psychopharmacology</i> , 1983 , 80, 1-9	4.7	27
3	The effects of naloxone, diprenorphine, and diazepam on responding suppressed by pre-shock and pre-food stimuli. <i>Life Sciences</i> , 1983 , 32, 479-86	6.8	6
2	Changeover ratio effects on concurrent variable-interval performance. <i>Journal of the Experimental Analysis of Behavior</i> , 1979 , 31, 239-52	2.1	3
1	Bias and Undermatching in Concurrent Chain-Pull Bar-Press Performance. <i>Psychological Record</i> , 1979 , 29, 103-109	1.1	1